Obligatory Responses to FDA Inspection Outcomes and Future Drug Shortages
- Yixin (Iris) Wang ,
Corresponding Author
Yixin (Iris) Wang
[email protected]https://orcid.org/0000-0003-3152-4539
Gies College of Business, University of Illinois Urbana-Champaign, Champaign, Illinois 61820
- George Ball ,
George Ball
[email protected]https://orcid.org/0000-0003-2585-0629
Kelley School of Business, Indiana University, Bloomington, Indiana 47405
- Gopesh Anand ,
Gopesh Anand
[email protected]https://orcid.org/0000-0002-5387-2027
Gies College of Business, University of Illinois Urbana-Champaign, Champaign, Illinois 61820
- Hyunwoo Park
Hyunwoo Park
[email protected]https://orcid.org/0000-0001-9818-217X
Graduate School of Data Science, Seoul National University, Seoul 08826, South Korea
Corresponding Author
Yixin (Iris) Wang
[email protected]https://orcid.org/0000-0003-3152-4539
Gies College of Business, University of Illinois Urbana-Champaign, Champaign, Illinois 61820
George Ball
[email protected]https://orcid.org/0000-0003-2585-0629
Kelley School of Business, Indiana University, Bloomington, Indiana 47405
Gopesh Anand
[email protected]https://orcid.org/0000-0002-5387-2027
Gies College of Business, University of Illinois Urbana-Champaign, Champaign, Illinois 61820
Hyunwoo Park
[email protected]https://orcid.org/0000-0001-9818-217X
Graduate School of Data Science, Seoul National University, Seoul 08826, South Korea

